{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:51:24Z","timestamp":1793325084881,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011112","name":"UCB US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01257-2","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T08:04:08Z","timestamp":1726473848000},"page":"2787-2804","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-3794","authenticated-orcid":false,"given":"Robert R.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-802X","authenticated-orcid":false,"given":"Silky W.","family":"Beaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-9987","authenticated-orcid":false,"given":"Adam P.","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7716-2727","authenticated-orcid":false,"given":"Jeffrey L.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-9782","authenticated-orcid":false,"given":"Laura","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-0915","authenticated-orcid":false,"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"issue":"1","key":"1257_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaad.2010.11.055","volume":"65","author":"A Menter","year":"2011","unstructured":"Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1257_CR2","first-page":"201","volume":"21","author":"SR Feldman","year":"2015","unstructured":"Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201\u20139.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1257_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","volume":"148","author":"S Hsu","year":"2012","unstructured":"Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol. 2012;148(1):95\u2013102.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1257_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-015-0092-3","volume":"6","author":"M Campa","year":"2016","unstructured":"Campa M, Mansouri B, Warren R, et al. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. Dermatol Ther. 2016;6(1):1\u201312.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1257_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","volume":"26","author":"L Grine","year":"2014","unstructured":"Grine L, Dejager L, Libert C, et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 2014;26(1):25\u201333.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"6","key":"1257_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313.","journal-title":"J Immunol"},{"issue":"6","key":"1257_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/dth.12267","volume":"28","author":"F Kerdel","year":"2015","unstructured":"Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28(6):390\u2013403.","journal-title":"Dermatol Ther"},{"issue":"1","key":"1257_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000504839","volume":"237","author":"E \u00d6zkur","year":"2021","unstructured":"\u00d6zkur E, K\u0131van\u00e7 Altunay \u0130, O\u011fuz Topal \u0130, et al. Switching biologics in the treatment of psoriasis: a multicenter experience. Dermatology. 2021;237(1):22\u201330.","journal-title":"Dermatology"},{"issue":"9","key":"1257_CR9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/1346-8138.13860","volume":"44","author":"H Honda","year":"2017","unstructured":"Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015\u20139.","journal-title":"J Dermatol"},{"issue":"11","key":"1257_CR10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1111\/jdv.18409","volume":"36","author":"R Curmin","year":"2022","unstructured":"Curmin R, Guillo S, De Rycke Y, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022;36(11):2101\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1257_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jaad.2012.06.035","volume":"68","author":"H Yeung","year":"2013","unstructured":"Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(1):64\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1257_CR12","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","volume":"13","author":"YC Tsai","year":"2020","unstructured":"Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13(5):493\u2013503.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"1257_CR13","first-page":"399","volume":"21","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Shi N, Murage M, et al. Long-term treatment patterns among patients with psoriasis treated with ixekizumab or adalimumab: a real-world study. J Drugs Dermatol. 2022;21(4):399\u2013407.","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"1257_CR14","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1185\/03007990802551057","volume":"24","author":"EQ Wu","year":"2008","unstructured":"Wu EQ, Feldman SR, Chen L, et al. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008;24(12):3493\u2013501.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"1257_CR15","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1346-8138.16543","volume":"49","author":"Y Tada","year":"2022","unstructured":"Tada Y, Kim H, Spanopoulos D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study. J Dermatol. 2022;49(11):1106\u201317.","journal-title":"J Dermatol"},{"issue":"6","key":"1257_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","volume":"74","author":"JA Doshi","year":"2016","unstructured":"Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"743180","key":"1257_CR17","first-page":"1","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;8(743180):1\u201312.","journal-title":"Front Med"},{"issue":"1","key":"1257_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1346-8138.16214","volume":"49","author":"MJ Gooderham","year":"2022","unstructured":"Gooderham MJ, Lynde C, Turchin I, et al. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. J Dermatol. 2022;49(1):95\u2013105.","journal-title":"J Dermatol"},{"issue":"2","key":"1257_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1257_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","volume":"25","author":"International Society for Pharmacoepidemiology","year":"2016","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practice (GPP). Pharmacoepidemiol Drug Saf. 2016;25(1):2\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"20","key":"1257_CR21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Assoc. 2013;310(20):2191\u20134.","journal-title":"J Am Med Assoc"},{"issue":"4","key":"1257_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2340\/00015555-1237","volume":"92","author":"I Flytstr\u00f6m","year":"2012","unstructured":"Flytstr\u00f6m I, Stenberg B, Svensson \u00c5, et al. Patients\u2019 visual analogue scale: a useful method for assessing psoriasis severity. Acta Derm Venereol. 2012;92(4):347\u20138.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1257_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1257_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659\u201364.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"1257_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1257_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/acr.22401","volume":"67","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, et al. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res. 2015;67(2):264\u201372.","journal-title":"Arthritis Care Res"},{"issue":"3","key":"1257_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","journal-title":"Health Policy"},{"key":"1257_CR28","first-page":"1","volume":"2022","author":"Y-L Lin","year":"2022","unstructured":"Lin Y-L, Huang A, Yang C-Y, et al. Measurement of body surface area for psoriasis using U-net models. Comput Math Methods Med. 2022;2022:1\u20139.","journal-title":"Comput Math Methods Med"},{"issue":"5","key":"1257_CR29","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"S Mahil","year":"2020","unstructured":"Mahil S, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1257_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/bimj.200390024","volume":"45","author":"KK Yau","year":"2003","unstructured":"Yau KK, Wang K, Lee AH. Zero-inflated negative binomial mixed regression modeling of over-dispersed count data with extra zeros. Biom J. 2003;45(4):437\u201352.","journal-title":"Biom J"},{"key":"1257_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2040622319843756","volume":"10","author":"T-Y Ger","year":"2019","unstructured":"Ger T-Y, Huang Y-H, Hui RC-Y, et al. Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement. Ther Adv Chronic Dis. 2019;10:1\u20139.","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"1257_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jdv.13990","volume":"31","author":"AB Gottlieb","year":"2017","unstructured":"Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two phase III randomized studies. J Eur Acad Dermatol Venereol. 2017;31(4):679\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1257_CR33","first-page":"320","volume":"179","author":"KA Papp","year":"2018","unstructured":"Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018;179(2):320\u20138.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1257_CR34","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1007\/s13555-021-00627-4","volume":"11","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Shi N, Burge R, et al. Comparison of real-world treatment patterns among biologic-experienced patients with psoriasis treated with ixekizumab or secukinumab over 18 months. Dermatol Ther. 2021;11(6):2133\u201345.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1257_CR35","first-page":"280","volume":"137","author":"G Krueger","year":"2001","unstructured":"Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280\u20134.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1257_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/jid.2013.326","volume":"134","author":"E Edson-Heredia","year":"2014","unstructured":"Edson-Heredia E, Sterling KL, Alatorre CI, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol. 2014;134(1):18\u201323.","journal-title":"J Invest Dermatol"},{"key":"1257_CR37","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41:917\u201325.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"1257_CR38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/JDD.2020.4957","volume":"19","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Wu JJ, Armstrong A, et al. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermat: JDD. 2020;19(5):487\u201392.","journal-title":"J Drugs Dermat: JDD"},{"issue":"2","key":"1257_CR39","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjd.15463","volume":"177","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Griffiths C, Lebwohl M, et al. Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. Br J Dermatol. 2017;177(2):587\u201390.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1257_CR40","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","volume":"135","author":"FJ Dalgard","year":"2015","unstructured":"Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984\u201391.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"1257_CR41","first-page":"1","volume":"25","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Tian H, Wang X, et al. Health care utilization and cost associated with biologic treatment patterns among patients with moderate to severe psoriasis: analyses from a large U.S. claims database. J Manag Care Spec Pharm. 2019;25(4):1\u201311.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1257_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1\u201310.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1257_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/09546634.2014.943687","volume":"26","author":"HN Viswanathan","year":"2015","unstructured":"Viswanathan HN, Chau D, Milmont CE, et al. Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat. 2015;26(3):235\u20139.","journal-title":"J Dermatol Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01257-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01257-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01257-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T17:07:33Z","timestamp":1729012053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01257-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01257-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"29 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew Blauvelt: Has served as a speaker (received honoraria) for Eli Lilly and Company\u00a0and UCB Pharma, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, CTI BioPharma, Dermavant Sciences, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Lipidio, Merck, Microbion, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant Sciences, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx, and owns stock in Lipidio and Oruka; Robert R. McLean, Adam P. Sima: Employees of CorEvitas, LLC; Silky W. Beaty: Employee at the time of the research and current shareholder of UCB Pharma; Robert Low, Jeffrey L. Stark, Laura McClung: Employees and shareholders of UCB Pharma; Jerry Bagel: Has received research funds payable to Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas, LLC, Dermavant Sciences, LTD, Dermira, UCB Pharma, Eli Lilly and Company, Glenmark Pharmaceuticals, Janssen, Kadmon Corporation, LEO Pharma, Lycera Corp, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro Pharmaceutical Industries Ltd., and Ortho Dermatologics; consultant fees from AbbVie, Amgen, Celgene, Bristol Myers Squibb, Eli Lilly and Company, Janssen, Novartis, Sun Pharma, UCB Pharma, and fees for speaking from AbbVie, Celgene, Eli Lilly and Company, Janssen, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice []. All participating investigators were required to obtain full board approval for conducting noninterventional research involving human subjects with a limited dataset. Sponsor approval and continuing review were obtained through a central Institutional Review Board (IRB), (Advarra, Protocol number Pro00051221). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC, before the site\u2019s participation and initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization before participating in the CorEvitas Psoriasis Registry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}